StockData

Roivant Sciences vs Viridian Therapeutics, Inc.\DE

ROIV and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ROIV and VRDN compare

Roivant Sciences is the larger company, worth 8.2 times as much as Viridian Therapeutics, Inc.\DE ($28.0B against $3.4B).

Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −67.6% for Roivant Sciences).

Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −3535% at Roivant Sciences.

Roivant Sciences scores higher on the StockData Score (7 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricROIVVRDN
Size and price
Market cap$28.0B$3.4B
Share price$38.71$30.06
Change, 1 year90.8%4.5%
Change, 5 years453%64.3%
Beta (5Y)0.42−0.13
Employees721252
StockData Score
Total score7 (better)4
Valuation score00
Growth score02 (better)
Performance score11
Health score6 (better)1
Dividend score00
Valuation
P/S3712×47.9× (better)
P/B6.6×5.1× (better)
FCF yield−2.9% (better)−9.8%
Fair value–$8.47
Margin of safety–−255%
Growth
Revenue growth (TTM)−67.6%23220% (better)
Revenue growth, 5Y average−19.1%132% (better)
Profitability
Operating margin−7915%−570% (better)
Net margin−3535%−544% (better)
FCF margin−10901%−471% (better)
Return on equity−6.2% (better)−65.7%
Return on invested capital−407%–
Financial health
Debt / equity0.00–
Interest coverage–−26.0×
Current ratio16.7216.95 (better)
Altman Z-score44.02 (better)2.65
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions78.1%120%
Held by insiders13.9%21.8%
Insider net buying, 12 months−$798M$19.6M (better)
Superinvestors holding1–
Short interest, % of float7.3%19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.